Enliven Therapeutics's market cap is currently $1.05B. The company's EPS TTM is $-1.906; its P/E ratio is ―; Enliven Therapeutics is scheduled to report earnings on March 13, 2025, and the estimated EPS forecast is $-0.52. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	$ -297.00K	$ -622.00K	$ -99.00K	$ -97.00K	$ -33.00K
Operating Income	$ -83.53M	$ -38.79M	$ -24.76M	$ -9.32M	$ -24.12M
EBITDA	$ -81.93M	$ -38.58M	$ -24.65M	$ -9.27M	$ -23.43M
Net Income	$ -71.58M	$ -37.75M	$ -24.72M	$ -18.93M	$ -23.46M
Balance Sheet
Cash & Short-Term Investments	$ 253.15M	$ 75.54M	$ 110.02M	$ 130.37M	$ 28.91M
Total Assets	$ 271.87M	$ 83.30M	$ 113.33M	$ 131.00M	$ 33.30M
Total Debt	$ 335.00K	$ 323.00K	$ 159.00K	$ 105.00K	$ 0.00
Net Debt	$ -99.81M	$ -75.21M	$ -109.86M	$ -130.26M	$ -4.94M
Total Liabilities	$ 25.96M	$ 160.12M	$ 156.22M	$ 151.31M	$ 4.38M
Stockholders' Equity	$ 245.91M	$ -76.83M	$ -42.89M	$ -20.30M	$ -48.85M
Cash Flow
Free Cash Flow	$ -61.42M	$ -32.69M	$ -19.32M	$ -8.99M	$ -22.02M
Operating Cash Flow	$ -61.27M	$ -32.08M	$ -19.13M	$ -8.53M	$ -21.88M
Investing Cash Flow	$ -148.41M	$ -612.00K	$ -191.00K	$ -461.00K	$ -24.06M
Financing Cash Flow	$ 234.29M	$ -1.80M	$ -1.02M	$ 130.51M	$ 43.58M

Currency in USD

Enliven Therapeutics Earnings and Revenue History

Income Statement >

Enliven Therapeutics Debt to Assets

Balance Sheet >

Enliven Therapeutics Cash Flow

Cash Flow >

Enliven Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing